Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NOS1AP
REST API REST API
Homo sapiens
NOS1AP is differentially expressed in 169 experiments: 99 organism parts: amygdala, thymus, ... (97 more);, 116 disease states: normal, healthy, ... (114 more);, 59 cell types 132 cell lines 13 compound treatments and 64 other conditions.
Synonyms CAPON, KIAA0464
Orthologs ENSCING00000008458 (Ciona intestinalis)   CA226_BOVIN (Bos taurus)   nos1apa (Danio rerio)   ENSGALG00000002749 (Gallus gallus)   CG42673 (Drosophila melanogaster)   CU693440.1 (Danio rerio)   nos1ap (Xenopus laevis)   NOS1AP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, PDZ domain binding, regulation of apoptosis, regulation of nitric-oxide synthase activity, regulation of nitric oxide biosynthetic process, nitric-oxide synthase binding
InterPro Term PTyr_interaction_dom
UniProt Accession B7ZLF5, O75052, Q3T551, E9PSG0, E9PIP8
Gene-Disease Assocation QT INTERVAL, VARIATION IN
Search EB-eye ENSG00000198929
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, E-GEOD-19480, ... (16 experiments)

Factor Value U/D Experiments
MCF-10A
2
E-TABM-420, E-GEOD-14990
A673
2
1
E-MTAB-37
BC3
1
1
E-MTAB-37
HEK293
1
E-MTAB-62
NCIH1436
1
E-MTAB-37
PLB985
1
E-MTAB-37
126 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, ... (31 experiments)

Factor Value U/D Experiments
monocyte
2
E-GEOD-22373, E-GEOD-8286
M1 macrophage
1
E-GEOD-5099
CD34 positive
1
E-GEOD-12662
neurosphere cell
1
E-MEXP-551
adrenal cortex cell
1
E-MEXP-669
white blood cell
1
E-GEOD-2006
53 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-TABM-15, E-GEOD-22148, E-GEOD-20602, ... (37 experiments)

Factor Value U/D Experiments
cancerous
1
E-TABM-15
NDV
1
E-GEOD-18791
ganglioneuroma
1
E-MTAB-62
SMLZ (Splenic Marginal Zone Lymphoma)
1
E-GEOD-16455
FKRP mutation
1
E-GEOD-3307
Non-decidualised
1
E-MTAB-680
110 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-412, E-TABM-127, E-GEOD-5824, ... (8 experiments)

Factor Value U/D Experiments
none
2
E-GEOD-412, E-GEOD-5824
heregulin
1
E-GEOD-6462
no estradiol
1
E-GEOD-20081
bacterial endotoxin
1
1
E-GEOD-3284
estradiol
4
1
E-GEOD-20081
not specified
1
E-GEOD-20081
7 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1563, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-20847

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-TABM-601, E-GEOD-17347 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-MEXP-1446

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-TABM-666, E-GEOD-19519, ... (22 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.554 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM